WAYNE, Pa., June 9 /PRNewswire/ -- Gerianne Tringali DiPiano, President and CEO of FemmePharma Global Healthcare, Inc., today announced that Sheri L. Risler, CPA has joined the Company’s management team as Vice President and Chief Financial Officer. In her position as CFO, Ms. Risler will oversee FemmePharma financial performance, planning and controls, fundraising activities and will also play a key role in the development of the Company’s overall business strategy.
Ms. Risler, a senior executive, joins FemmePharma Global Healthcare, Inc. from Ernst & Young, LLP, where she was a Partner in the Emerging and Growth Markets Practice serving entrepreneurially managed life science and technology based companies in the middle market for the past 20 years. Most recently Ms. Risler was the 2004 Co-Chair of the Mid-Atlantic Venture Conference in Philadelphia and for the past 10 years had been the leader of the Ernst and Young Entrepreneur of the Year program.
“We are pleased to have Sheri join our team at FemmePharma Global Healthcare, Inc. Her proven record of success and financial leadership provides her with the ability to contribute to our finance, operations and business strategy and will benefit us as we pursue our corporate initiatives,” said Tringali DiPiano.
Ms. Risler received a Bachelor of Science degree in Business Administration, with a concentration in accounting from Boston University and is a certified public accountant in Pennsylvania.
About FemmePharma Global Healthcare, Inc.
FemmePharma Global Healthcare, Inc. was founded by Gerianne Tringali DiPiano to target high unmet medical needs within the estimated $70 billion women’s healthcare pharmaceutical market. The Company is committed to developing safe and effective drugs that minimize or eliminate the systemic side effects associated with many drug therapies by designing them in a way that is specifically suited to a woman’s physiology with an eye toward the changing needs of women throughout their lives. FemmePharma currently has a product to treat urinary incontinence in Phase 2 and has two other products in the areas of fibrocystic breast disease and dysfunctional uterine bleeding in preclinical development. For more information about FemmePharma, please visit its website at http://www.fpghc.com.
FemmePharma Global Healthcare, Inc.
CONTACT: Gerianne Tringali DiPiano, FemmePharma Global Healthcare,+1-610-995-0801
Web site: http://www.fpghc.com/